Hong Kong, 3 July 2026—Zai Lab Limited announced the first awards under its 2024 Equity Incentive Plan, comprising both share options and restricted share units (RSUs) granted on 2 July 2026 (U.S. Eastern Time).

A single employee received 2,000 American depositary share (ADS) options—equivalent to 20,000 ordinary shares—at an exercise price of US$19.12 per ADS (about HK$14.91 per share). The options carry a ten-year term and vest in four equal annual tranches, contingent on continued employment.

The RSU component totals 84,893 ADSs (848,930 ordinary shares). Of these, 80,393 ADSs were awarded to Chairperson and CEO Dr. Samantha Du, while 4,500 ADSs were distributed among three other employees. RSUs require no purchase price and vest 25% annually over four years, also subject to continued service.

All awards were issued at the ADS closing price of US$19.12 (HK$14.99 per share on the Hong Kong market) recorded on the grant date. No performance targets or claw-back provisions apply, a structure the Board’s Compensation Committee considers consistent with market practice and the plan’s objectives.

Following the transaction, 59.42 million ordinary shares remain available for future grants under the scheme mandate limit of the 2024 Equity Incentive Plan.

The independent directors approved the RSU grant to Dr. Du, and the awards comply with Hong Kong Listing Rules limits on individual and aggregate equity issuances. No financial assistance is being provided to recipients for share purchases.